GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
DC15-MM-01
Phase 1 Terminated
4 enrolled
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
183 enrolled
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
IFM2014-01
Phase 2 Terminated
26 enrolled
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Phase 1/2 Terminated
14 enrolled
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
60 enrolled
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
3 enrolled
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
19 enrolled 22 charts
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Phase 1 Terminated
11 enrolled
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
47 enrolled
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
6 enrolled 10 charts
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1/2 Terminated
9 enrolled 13 charts
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Phase 1 Terminated
4 enrolled
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Phase 2 Terminated
45 enrolled
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Phase 1 Terminated
9 enrolled
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Phase 1 Terminated
8 enrolled
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase 1 Terminated
6 enrolled 19 charts
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase 3 Terminated
269 enrolled 9 charts
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Phase 1/2 Terminated
17 enrolled
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
Phase 1 Terminated
8 enrolled
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
Phase 2 Terminated
20 enrolled
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
15 enrolled
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
Phase 1 Terminated
41 enrolled 32 charts
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
48 enrolled 10 charts
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase 3 Terminated
147 enrolled
rev/abraxane
Phase 1/2 Terminated
3 enrolled 3 charts
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Terminated
19 enrolled 10 charts
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Terminated
1,000 enrolled
Efficacy Study of CYT997 in Multiple Myeloma
Phase 2 Terminated
5 enrolled
DexTR
Phase 2 Terminated
5 enrolled 8 charts
CLC-102
Phase 1 Terminated
120 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase NA Terminated
43 enrolled
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 1 chart
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
Phase NA Terminated
16 enrolled 6 charts
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
Phase 1 Terminated
1 enrolled
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Phase 2 Terminated
22 enrolled 9 charts
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled 3 charts
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Phase 1 Terminated
11 enrolled
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
6 enrolled 6 charts
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Terminated
48 enrolled
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
9 enrolled
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Phase 2 Terminated
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Phase NA Terminated
4 enrolled